Arca
Skip to content
Tools
Tools

-tide

A peptide: a short chain of amino acids. Many hormone-like drugs carry it, often with a more specific stem in front.

  • Drugs ending in -tide: 160
  • Approved somewhere: 34
  • With a US drug page: 35

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-tide
Class
Peptides
Most common targets
GLP1R (16), GCGR (4), PTH1R (4), SSTR5 (4), SSTR2 (4), GUCY2C (3), MC1R (2), MC4R (2)

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -tide or one of its sub-stems, matched by spelling; those with a US drug page link to it.
Acts on
AfamelanotideApprovedMC1RMelanocortin receptor 1 agonist
BremelanotideApprovedMC4RMelanocortin receptor 4 agonist
BulevirtideApprovedSLC10A1Bile acid transporter inhibitor
Defibrotide sodiumApprovedPLGPlasminogen activator
EcallantideApprovedKLKB1Plasma kallikrein inhibitor
EnfuvirtideApprovedENVTransmembrane glycoprotein gp41 inhibitor
EptifibatideApprovedITGA2B, ITGB3Integrin alpha-IIb/beta-3 inhibitor
EtelcalcetideApprovedCASRCalcium sensing receptor agonist
LinaclotideApprovedGUCY2CHeat-stable enterotoxin receptor agonist
Motixafortide acetateApproved——
PlecanatideApprovedGUCY2CHeat-stable enterotoxin receptor agonist
PramlintideApprovedCALCR, RAMP1, CALCR, RAMP3, CALCR, RAMP2Amylin receptor AMY1, CALCR/RAMP1 agonist
SetmelanotideApprovedMC4RMelanocortin receptor 4 agonist
TirzepatideApprovedGIPR, GLP1RGastric inhibitory polypeptide receptor agonist
ZiconotideApprovedCACNA1BVoltage-gated N-type calcium channel alpha-1B subunit blocker
Ziconotide acetateApprovedCACNA1BVoltage-gated N-type calcium channel alpha-1B subunit blocker
DefibrotidePhase 3ADORA2A, ADORA2B, PLG, ADORA1, F2Adenosine A2 receptor agonist
ElamipretidePhase 3——
MotixafortidePhase 3CXCR4C-X-C chemokine receptor type 4 antagonist
PeginesatidePhase 3EPORErythropoietin receptor agonist
RusfertidePhase 3——
Rusfertide acetatePhase 1——
Setmelanotide hydrochloridePhase 1——
GozetotideApproved—Diagnostic agent
Mifamurtide acidApprovedNOD2Nucleotide-binding oligomerization domain-containing protein 2 other
Vipivotide tetraxetan lutetiumApprovedFOLH1, DNAGlutamate carboxypeptidase II binding agent
AclerastidePhase 3——
AlbuvirtidePhase 3ENV, HIV1GP41 inhibitor
AvexitidePhase 3GLP1RGlucagon-like peptide 1 receptor antagonist
BalixafortidePhase 3CXCR4C-X-C chemokine receptor type 4 antagonist
Brimapitide, c-terminal acidPhase 3MAPK10c-Jun N-terminal kinase 3 inhibitor
CagrilintidePhase 3——
CilengitidePhase 3ITGAV, ITGB3, ITGAV, ITGB5Integrin alpha-V/beta-3 antagonist
DirucotidePhase 3——
EnlicitidePhase 3——
FexapotidePhase 3——
LarazotidePhase 3CHRNA3, CHRNB4Neuronal acetylcholine receptor; alpha3/beta4 partial agonist
RetatrutidePhase 3GCGR, GLP1R, GIPRGlucagon receptor agonist
SovatelitidePhase 3——
Alizulatide vixocianinePhase 2——
AnfibatidePhase 2GP1BAPlatelet glycoprotein Ib alpha chain antagonist
CertepetidePhase 2——
DanegaptidePhase 2——
DavalintidePhase 2CALCRL, CALCR, RAMP1Calcitonin gene-related peptide type 1 receptor agonist
DazdotuftidePhase 2——
DolcanatidePhase 2GUCY2CHeat-stable enterotoxin receptor agonist
DusquetidePhase 2——
EdratidePhase 2——
EtarfolatidePhase 2——
HepalatidePhase 2SLC10A1Bile acid transporter inhibitor
LancovutidePhase 2——
LivoletidePhase 2——
LucicebtidePhase 2——
MibenratidePhase 2—Unknown
ModimelanotidePhase 2MC3R, MC1RMelanocortin receptor 3 agonist
NangibotidePhase 2TREM1Triggering receptor expressed on myeloid cells 1 inhibitor
OlatorepatidePhase 2——
PaluratidePhase 2——
PegmispotidePhase 2——
Peptide tPhase 2——
Peptide yy human (3-36)Phase 2NPY2RNeuropeptide Y receptor type 2 agonist
PezadeftidePhase 2——
PobrolitidePhase 2——
RecanaclotidePhase 2——
RedasemtidePhase 2——
RimtoregtidePhase 2——
RotigaptidePhase 2——
RusalatidePhase 2——
SolnatidePhase 2——
SulglicotidePhase 2——
TalfirastidePhase 2MAS1Proto-oncogene Mas agonist
Talogreptide mesaroxetanPhase 2——
TozuleristidePhase 2—Diagnostic
Vanutide cridificarPhase 2APPAmyloid-beta A4 protein vaccine antigen
Vipivotide tetraxetan galliumPhase 2——
Zelenectide pevedotinPhase 2——
Avexitide acetatePhase 1——
BrimapitidePhase 1MAPK10c-Jun N-terminal kinase 3 inhibitor
ColulintidePhase 1——
DalazatidePhase 1——
EloralintidePhase 1——
GersizangitidePhase 1——
MacupatidePhase 1——
NisotirostidePhase 1——
NoraramtidePhase 1——
PegloprastidePhase 1——
Peptide B27PDPhase 1——
PetrelintidePhase 1——
RugecitidePhase 1——
RuxotemitidePhase 1——
TifuvirtidePhase 1——
TigapotidePhase 1——
Vipivotide tetraxetanPhase 1——
XelafaslatidePhase 1——
ZelenectidePhase 1——
ZendusortidePhase 1——
Ceruletide—CCKARCholecystokinin A receptor agonist
MazdutidePhase 3——
CotadutidePhase 2GCGR, GLP1RGlucagon receptor agonist
EfinopegdutidePhase 2GLP1R, GCGRGlucagon-like peptide 1 receptor agonist
PegapamodutidePhase 2GLP1RGlucagon-like peptide 1 receptor agonist
PemvidutidePhase 2——
SurvodutidePhase 1GLP1R, GCGRGlucagon-like peptide 1 receptor agonist
ExenatideApprovedGLP1RGlucagon-like peptide 1 receptor agonist
LixisenatideApprovedGLP1RGlucagon-like peptide 1 receptor agonist
EfpeglenatidePhase 3GLP1RGlucagon-like peptide 1 receptor agonist
PegsebrenatidePhase 2GLP1RGlucagon-like peptide 1 receptor agonist
VurolenatidePhase 2——
PegloxenatidePhase 1——
AlbiglutideApprovedGLP1RGlucagon-like peptide 1 receptor agonist
DulaglutideApprovedGLP1RGlucagon-like peptide 1 receptor agonist
LiraglutideApprovedGLP1RGlucagon-like peptide 1 receptor agonist
SemaglutideApprovedGLP1RGlucagon-like peptide 1 receptor agonist
TeduglutideApprovedGLP2RGlucagon-like peptide 2 receptor agonist
EcnoglutidePhase 3——
GlepaglutidePhase 3——
TaspoglutidePhase 3GLP1RGlucagon-like peptide 1 receptor agonist
ElsiglutidePhase 2GLP2RGlucagon-like peptide 2 receptor agonist
FroniglutidePhase 2——
Beinaglutide———
TecemotidePhase 3MUC1Mucin-1 vaccine antigen
TertomotidePhase 3——
AmilomotidePhase 2APPAmyloid-beta A4 protein vaccine antigen
DisomotidePhase 2——
EderimotidePhase 2——
EnavermotidePhase 2——
EtimumotidePhase 2——
ImsamotidePhase 2——
MarlumotidePhase 2——
OmramotidePhase 2——
OvemotidePhase 2——
OximbomotidePhase 2——
QuazomotidePhase 2——
SucantomotidePhase 2——
TiplimotidePhase 2——
VorumotidePhase 2——
BaloramotidePhase 1——
ElpamotidePhase 1——
TrofinetideApproved—Unknown
NerinetidePhase 3——
DavunetidePhase 2TubulinTubulin stabiliser
CibinetidePhase 1CSF2RB, EPORInnate repair receptor agonist
AbaloparatideApprovedPTH1RParathyroid hormone receptor agonist
PalopegteriparatideApprovedPTH1RParathyroid hormone receptor agonist
TeriparatideApprovedPTH1RParathyroid hormone receptor agonist
Teriparatide acetatePhase 3PTH1RParathyroid hormone receptor agonist
EneboparatidePhase 1——
Zelpultide alfaPhase 1——
LanreotideApprovedSSTR5, SSTR2Somatostatin receptor 5 agonist
OctreotideApprovedSomatostatin receptorSomatostatin receptor agonist
Depreotide trifluoroacetateApproved—Diagnostic agent
PasireotideApprovedSSTR5, SSTR2, SSTR1, SSTR3Somatostatin receptor 5 agonist
EdotreotidePhase 3——
VapreotidePhase 3SSTR2, SSTR3, SSTR5Somatostatin receptor 2 agonist
PentetreotidePhase 2——
Ucasareotide dasaroxetanPhase 2——
VeldoreotidePhase 2SSTR2, SSTR4, SSTR5Somatostatin receptor 2 agonist
Nendratareotide uzatansinePhase 1——
Satoreotide tetraxetanPhase 1——
Satoreotide trizoxetanEarly phase 1——

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.